Top Tweets for #Capitello281
Exciting phase 3 trials data in metastatic #ProstateCancer @myESMO #ESMO26 #ESMOAmbassadors #PEACE1 #Capitello281 @Silke_Gillessen @neerajaiims @OncoAlert @OncBrothers @PCFnews @shilpaonc @EAntonarakis @Parminder1699 @Uromigos @montypal @docjavip @drenriquegrande @cdanicas
#ESMO26: Adding capivasertib to abiraterone and adding abiraterone to standard care resulted in significant improvements in #ProstateCancer in the phase III CAPItello-281 and PEACE-1 #ClinicalTrials, as discussed by Elena Castro
🔗 https://t.co/OvTWVzKZll
#InsightsbyESMO
#ScienceLink #Madrid2026 #ESMO26 #CAPItello281 #PTEN
En la actualización de CAPItello-281 (fase III; n=1012), capivasertib + abiraterona mostró resultados favorables frente a placebo + abiraterona en cáncer de próstata metastásico hormonosensible de novo con deficiencia de PTEN. Ambos grupos recibieron TDA.
⏰ 17 meses adicionales de seguimiento
📊 SG: 57.4 vs 46.5 meses
HR 0.82 (IC 95%: 0.68–0.99; p=0.044)
⏳ SLPr: 35.5 vs 26.0 meses
HR 0.83 (IC 95%: 0.70–0.99)
⚠️ Análisis descriptivo: la SG no alcanzó el umbral de significancia estadística establecido.
Seguridad consistente con el análisis primario; destacan diarrea, hiperglucemia y exantema.
🔗 Leer/escuchar noticia completa: https://t.co/iwvKZI0RMp
Lovely walking tour & sunset in Madrid @myESMO #ESMO26
Looking forward today to:
#VOLGA peri-op durva/treme/EV MIBC & Daro in very high risk PCa both in presidential session🌟
#KNB15 ctDNA analysis
Claudin-6 ADC in GCT
#CAPITELLO281 capi OS in mCSPC
NAT ICI in penile CA
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
We touched on 6 studies (3 from #ASCO26 and 3 recent @FDAOncology ✅) during our GU Malignancies Conference Highlights w/ @Uromigos
⭐️ #PROTEUS
⭐️ #TALAPRO3
⭐️ #EV302
✅ #POTOMAC
✅ #CAPItello281
✅ #LITESPARK022
#OncTwitter #gusm @OncUpdates
GU Malignancies Conference Highlights from #ASCO26 (and recent @US_FDA ✅) w/ @Uromigos
⭐️ #PROTEUS
⭐️ #TALAPRO3
⭐️ #EV302
✅ #POTOMAC
✅ #CAPItello281
✅ #LITESPARK022
Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ https://t.co/DOo4V61t61
#OncTwitter @OncUpdates
GU Malignancies Conference Highlights from #ASCO26 (and recent @US_FDA ✅) w/ @Uromigos
⭐️ #PROTEUS
⭐️ #TALAPRO3
⭐️ #EV302
✅ #POTOMAC
✅ #CAPItello281
✅ #LITESPARK022
Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ https://t.co/DOo4V61t61
#OncTwitter @OncUpdates
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai
Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
Last Seen Hashtags on Sotwe
ipcam
Seen from Chile
anxiouspandaa(*)***filter:videos
Seen from Norway
DLMen
Seen from Japan
Bimbo
Seen from Ukraine
سِِكُسْ
Seen from Netherlands
minichats
Seen from Italy
抖音走光
Seen from United States
codersandprogrammers
Seen from United States
gay #ai #asian
معصيتّيَ_رِحّتِي
Seen from Netherlands
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers